Sigma Planning Corp Sells 2,464 Shares of Becton, Dickinson and Company (NYSE:BDX)

Sigma Planning Corp decreased its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 49.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,561 shares of the medical instruments supplier’s stock after selling 2,464 shares during the quarter. Sigma Planning Corp’s holdings in Becton, Dickinson and Company were worth $624,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Jeppson Wealth Management LLC increased its position in shares of Becton, Dickinson and Company by 4.0% during the 3rd quarter. Jeppson Wealth Management LLC now owns 1,028 shares of the medical instruments supplier’s stock valued at $266,000 after purchasing an additional 40 shares during the last quarter. CX Institutional grew its position in Becton, Dickinson and Company by 3.0% during the 3rd quarter. CX Institutional now owns 1,491 shares of the medical instruments supplier’s stock worth $385,000 after acquiring an additional 43 shares during the last quarter. U.S. Capital Wealth Advisors LLC grew its position in Becton, Dickinson and Company by 3.4% during the 3rd quarter. U.S. Capital Wealth Advisors LLC now owns 1,310 shares of the medical instruments supplier’s stock worth $339,000 after acquiring an additional 43 shares during the last quarter. Value Partners Investments Inc. grew its position in Becton, Dickinson and Company by 5.2% during the 3rd quarter. Value Partners Investments Inc. now owns 867 shares of the medical instruments supplier’s stock worth $225,000 after acquiring an additional 43 shares during the last quarter. Finally, Atlas Private Wealth Management grew its position in Becton, Dickinson and Company by 2.9% during the 3rd quarter. Atlas Private Wealth Management now owns 1,587 shares of the medical instruments supplier’s stock worth $410,000 after acquiring an additional 45 shares during the last quarter. Institutional investors own 86.97% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Raymond James raised their price target on Becton, Dickinson and Company from $269.00 to $275.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 3rd. Barclays lifted their price objective on Becton, Dickinson and Company from $301.00 to $305.00 and gave the stock an “overweight” rating in a research report on Monday, February 5th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $280.00.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, SVP Thomas J. Spoerel sold 282 shares of Becton, Dickinson and Company stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $238.29, for a total transaction of $67,197.78. Following the completion of the transaction, the senior vice president now owns 2,276 shares in the company, valued at $542,348.04. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.31% of the stock is owned by company insiders.

Becton, Dickinson and Company Trading Down 0.3 %

BDX opened at $233.73 on Thursday. The stock has a market cap of $67.52 billion, a PE ratio of 55.39, a PEG ratio of 1.93 and a beta of 0.43. The company has a quick ratio of 0.64, a current ratio of 1.08 and a debt-to-equity ratio of 0.56. The business has a 50 day moving average of $239.62 and a 200-day moving average of $241.73. Becton, Dickinson and Company has a 52 week low of $229.40 and a 52 week high of $287.32.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, February 1st. The medical instruments supplier reported $2.68 EPS for the quarter, beating analysts’ consensus estimates of $2.39 by $0.29. The company had revenue of $4.71 billion during the quarter, compared to analysts’ expectations of $4.73 billion. Becton, Dickinson and Company had a return on equity of 13.57% and a net margin of 6.44%. The firm’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same quarter last year, the business posted $2.98 EPS. Equities research analysts predict that Becton, Dickinson and Company will post 12.94 earnings per share for the current fiscal year.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.